Viewing Study NCT02003092

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:35 PM
Ignite Modification Date: 2026-02-26 @ 2:14 AM
Study NCT ID: NCT02003092
Status: TERMINATED
Last Update Posted: 2020-01-06
First Post: 2013-11-15
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
Sponsor: Rexahn Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Solid Tumor View
None Triple Negative Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic View
None Rexahn View
None Phase 1 View
None Triple Negative Breast Cancer View
None Phase 2 View
None Relapsed View